BioCentury
ARTICLE | Product Development

Now grown up, independent biotechs bulk up their platforms with more modalities

Why Regeneron and Seattle Genetics are adding new modalities onto the platforms that got them to market

May 11, 2019 12:46 AM UTC

As the incoming class of independent biotechs look to build on their clinical and commercial successes, a handful are expanding beyond the technology that got them there, bringing in new modalities to complement their platforms and bolster their core focus areas.

It’s become clear that more biotechs are taking the commercial reins for their own products. An April analysis by BioCentury found a steady rise in the number of biotechs launching their first commercial products in the U.S. over the last five years (see “Rise of the Independents: Biotechs Go to Market”)...